ACRO BIOMEDICAL CO., LTD. (ACBM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ACRO BIOMEDICAL CO., LTD. (ACBM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Yu-Ting, Su resigned as director, chairman and chief executive officer of the Company, effective upon
How this was made
The 30-second read
Why it matters
The appointments introduce executives with experience in AI, digital platforms, and food‑service tech, which may influence future strategic initiatives.
Market read
Primary corporate action for a micro‑cap; may trigger short‑term price movement but limited broader market impact.
What to watch
Potential synergies from CEO's background in AI‑driven platforms and cloud‑kitchen operations.
Background
The filing is a standard SEC Form 8‑K disclosure of director and officer changes for Acro Biomedical Co., Ltd.
Ticker impact
SEC 8‑K reports resignation of CEO/chair Yu‑Ting Su and appointment of new chairman Shao‑Hsiang Shih and CEO/CFO Jing‑Zhou Chen effective Sep 2 2026.
Potential short‑term volatility as investors reassess management team.
New executives bring different experience; market reaction uncertain for a micro‑cap.
Market effects
Minimal; leadership change does not directly impact sector trends.
Limited to Taiwan biotech/tech niche where the company operates.
Low; no broader market effect expected.
Counterpoint
New management could accelerate growth if execution improves, offering upside beyond typical micro‑cap volatility.
Key entities
- personYu‑Ting Su
Resigned as director, chairman and CEO.
- personShao‑Hsiang Shih
Appointed new chairman.
- personJing‑Zhou Chen
Appointed CEO and CFO.
